| Literature DB >> 19734209 |
Marina Noris1, Paola Cassis, Nadia Azzollini, Regiane Cavinato, Daniela Cugini, Federica Casiraghi, Sistiana Aiello, Samantha Solini, Linda Cassis, Marilena Mister, Marta Todeschini, Mauro Abbate, Ariela Benigni, Piera Trionfini, Susanna Tomasoni, Caterina Mele, Cecilia Garlanda, Nadia Polentarutti, Alberto Mantovani, Giuseppe Remuzzi.
Abstract
Members of the TLR/IL-1R superfamily mediate ischemia/reperfusion injury and initiate immune response in transplanted organs. In this study, we tested the hypothesis that Toll-IL-1R8 (TIR8), a negative regulator of TLR/IL-1R highly expressed in the kidney, modulates immune cell activation underlying kidney rejection. In a mouse model of fully mismatched kidney allotransplantation in which the graft is spontaneously accepted, intragraft Tir8 expression was enhanced compared with naive kidneys. Targeted deletion of Tir8 in the graft exerted a powerful antitolerogenic action leading to acute rejection. Similarly, in a mouse model of kidney graft acceptance induced by costimulation blockade, most Tir8(-/-) grafts were acutely rejected. Despite similar levels of TLR4, IL-1R, and their ligands, the posttransplant ischemia/reperfusion-induced inflammatory response was more severe in Tir8(-/-) than in Tir8(+/+) grafts and was followed by expansion and maturation of resident dendritic cell precursors. In vitro, Tir8(-/-) dendritic cell precursors acquired higher allostimulatory activity and released more IL-6 upon stimulation with a TLR4 ligand and TNF-alpha than Tir8(+/+) cells, which may explain the increased frequency of antidonor-reactive T cells and the block of regulatory T cell formation in recipients of a Tir8(-/-) kidney. Thus, TIR8 acts locally as a key regulator of allogeneic immune response in the kidney. Tir8 expression and/or signaling in donor tissue are envisaged as a novel target for control of innate immunity and amelioration of graft survival.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19734209 DOI: 10.4049/jimmunol.0803549
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422